The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Verona Pharma Plc ADR shares valued at $922,000 were sold by Fisher Andrew on Jun 16 ’25. At $11.53 per share, Fisher Andrew sold 80,000 shares. The insider’s holdings dropped to 359,999 shares worth approximately $34.24 million following the completion of this transaction.
Also, Hahn Mark W sold 400,000 shares, netting a total of over 4,560,360 in proceeds. Following the sale of shares at $11.40 each, the insider now holds 12,278,992 shares.
Before that, ZACCARDELLI DAVID had sold 400,000 shares from its account. In a trade valued at $4,560,520, the President and CEO traded Verona Pharma Plc ADR shares for $11.40 each. Upon closing the transaction, the insider’s holdings decreased to 400,000 shares, worth approximately $1.25 billion.
As published in their initiating research note from TD Cowen on April 28, 2025, Verona Pharma Plc ADR [VRNA] has been a Buy and the price target has been revised to $100. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of January 10, 2025, ROTH MKM has initiated its “Buy” rating for VRNA. Earlier on October 03, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for VRNA stock.
Analyzing VRNA Stock Performance
On last trading session,, Verona Pharma Plc ADR [NASDAQ: VRNA] plunged -2.17% to $95.11. The stock’s lowest price that day was $94.95, but it reached a high of $97.6129 in the same session. During the last five days, there has been a surge of approximately 2.35%. Over the course of the year, Verona Pharma Plc ADR shares have jumped approximately 534.07%. Shares of the company reached a 52-week high of $99.01 on 06/24/25 and a 52-week low of $43.44 on 01/10/25.
Support And Resistance Levels for Verona Pharma Plc ADR (VRNA)
According to the 24-hour chart, there is a support level at 94.17, which, if violated, would cause prices to drop to 93.23. In the upper region, resistance lies at 96.83. The next price resistance is at 98.55. RSI (Relative Strength Index) is 71.47 on the 14-day chart, showing overbought technical sentiment.
Is Verona Pharma Plc ADR subject to short interest?
Stocks of Verona Pharma Plc ADR saw a sharp steep in short interest on 2025-05-30 dropping by -0.87 million shares to 7.13 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 8.0 million shares. A decline of -12.15% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.38 of the overall float, the days-to-cover ratio (short ratio) decline to 5.38.
Which companies own the most shares of Verona Pharma Plc ADR (VRNA)?
In terms of Verona Pharma Plc ADR share price expectations, FactSet research, analysts set an average price target of 77.5 in the next 12 months, down nearly -20.28% from the previous closing price of $97.22. Analysts anticipate Verona Pharma Plc ADR stock to reach 83 by 2025, with the lowest price target being 74. In spite of this, 7 analysts ranked Verona Pharma Plc ADR stock as Buy at the end of 2025. On May 22, 2023, Jefferies assigned a price target of “a Buy” to the stock and resumed coverage with a $38.
